VBI Vaccines Inc. (VBIV)

0.6699 +0.0330 (+5.18%) As of 03:34PM EDT. Market open.

VBI Vaccines Inc.

160 Second Street
3rd Floor
Cambridge, MA 02142
United States
617 830 3031
https://www.vbivaccines.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 131

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jeffery R. Baxter FCMA	President, CEO & Director	771.81k	N/A	1961
Ms. Nell Beattie	CFO, Head of Corporate Development & Director	N/A	N/A	1988
Dr. David Evander Anderson	Chief Scientific Officer	473.25k	N/A	1970
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.	Chief Medical Officer	457.92k	N/A	1955
Nicole Anderson	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Athena Kartsaklis	Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer	N/A	N/A	1965
Mr. Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	N/A	N/A	1962
Mr. Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	N/A	N/A	N/A
Mr. T. Adam Buckley	Senior Vice President of Business Development	N/A	N/A	1976
Mr. John Robert Dillman	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Corporate governance

VBI Vaccines Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.